BeiGene News
- May 29, 2020BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
- May 29, 2020BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
- May 26, 2020BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
- May 26, 2020Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
- May 21, 2020BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
- May 20, 2020BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
- BeiGene Facts
- Founded 2010
- Listings NASDAQ: BGNE
HKEX: 06160 - Internally Developed
Clinical Candidates 7 - Marketed
Products
in China 4 - Approved
products
in the U.S.1 - Global Team 3800+
2010
- BeiGene was founded as a research and development company
2012
- Began work on an anti-PD-1 antibody and a BTK inhibitor
2014
- Started clinical trials of pamiparib and zanubrutinib
2016
- Went public on the Nasdaq, with $182 million initial public offering
2018
- 50+ ongoing or planned clinical trials
2019
- Received first FDA approval for BRUKINSA™ (zanubrutinib)
- Received first approval for tislelizumab in China
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.